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Comparison of three enzyme-linked immunosorbent assays to detect
Porcine circovirus-2 (PCV-2)–specific antibodies after vaccination or
inoculation of pigs with distinct PCV-1 or PCV-2 isolates
Abby R. Patterson, John Johnson, Sheela Ramamoorthy, Xiang-Jin Meng, Patrick G. Halbur,
Tanja Opriessnig1
Abstract. Porcine circovirus-2 (PCV-2) serology is frequently used to determine PCV-2 status and optimal
timing of PCV-2 vaccination in the field. The objectives of the current study are to determine the diagnostic
accuracy of 3 currently available commercial anti-immunoglobulin G (IgG) PCV-2 enzyme-linked
immunosorbent assays (ELISAs) and to compare the ability of the 3 assays to detect and differentiate
between anti–PCV-2a and anti–PCV-2b antibodies, as well as anti–PCV-2 and anti–PCV-1 antibodies. Fifty-
five 3-week-old, conventional pigs were randomly allocated to 7 groups: 1) negative controls (n 5 7), 2) PCV-
2a (n5 8; inoculated with PCV-2 ISU-40895), 3) PCV-2b (n5 8; inoculated with PCV-2 NC-16845), 4) PCV-1
(n 5 8), 5) vaccine A (n 5 8; IngelvacH CircoFLEXTM), 6) vaccine B (n 5 8; CircumventH PCV2), and 7)
vaccine C (n5 8; SuvaxynH PCV2 One Dose). Blood samples were collected weekly, and all sera were tested by
3 different anti–PCV-2 IgG ELISAs. The results indicated that all ELISAs had area under the receiver
operating curve values greater than 0.94, detected both anti–PCV-2a and -2b antibodies with no
differentiation, and did not detect anti–PCV-1 antibodies in infected animals. One of the ELISAs was able
to distinguish pigs vaccinated with vaccine B from pigs inoculated with either PCV-2a or PCV-2b.
Key words: Antibodies; enzyme-linked immunosorbent assay; Porcine circovirus-2; serology; vaccination.
Introduction
Porcine circovirus (PCV; family Circoviridae; genus
Circovirus) was first identified as a contaminant of the
permanent porcine kidney cell line PK-15 in 1974.26
The virus is nonenveloped and composed of a single-
stranded, circular DNA genome. Two major types of
PCV have been identified, PCV type 1 (PCV-1) and
type 2 (PCV-2).19 Porcine circovirus-1 has been shown
to be nonpathogenic in pigs under experimental
conditions.1,27 In contrast, infection with PCV-2 has
been associated with respiratory disease, enteritis,
reproductive failure, porcine dermatitis and nephrop-
athy syndrome, and systemic infections, which are
known as Porcine circovirus–associated disease or
PCVAD.22 While the pathogenesis of PCVAD re-
mains unclear, it can result in high levels of PCV-2
viremia in 5% to 30% of a swine population. In
affected animals, mortality can reach 70% to 80%.22
Based on sequence analyses of PCV-2, type 2 can
be further divided into 2 main phylogenetic clusters,
PCV-2a and PCV-2b.5 The PCV-2 genome is com-
posed of 2 known open reading frames (ORFs) that
code for functional proteins. The ORF1 gene encodes
for a replication-associated protein (Rep), which is
essential for virus replication.4 The ORF2 gene
encodes for the capsid protein, which has been shown
to be immunogenic20,21 and which has a greater
nucleotide variation than ORF1.15
Several commercial PCV-2 vaccines became avail-
able in North America in 2006. As of January 2008, 3
products are fully licensed and available in the United
States for use in healthy pigs. Two of the vaccines
contain the PCV-2 capsid protein expressed in a
baculovirus (BA) system as an antigen.6,8 The third
vaccine is composed of an inactivated PCV-1–2
chimera virus.7 Other notable differences between
the 3 vaccines include the dose and timing of
administration: 2-ml versus 1-ml injections and 1-
time administration versus booster vaccination.22
The release of PCV-2 vaccines provides an im-
petus for assessing the PCV-2 status of herds to
determine the best time for vaccination. One
method of assessing when and if PCV-2 is circulating
in a herd is to conduct a cross-sectional serological
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survey to determine the prevalence and levels of anti–
PCV-2 antibodies over time using 1 or more of the
serological tests for PCV-2 including various enzyme-
linked immunosorbent assays (ELISAs).3,16,20,25,29,30
Most ELISA tests use the ORF2 region as antigen
since it is specific and immunogenic for PCV-2.28
Although most assays are based on PCV-2 ORF2, the
methods of antigen production differ among assays.
Specifically, antigen has been produced by expression
of the capsid protein in a BA vector system,3,16,20 in
live virus preparations in PK-15 cells,29 or through
expression in Escherichia coli.25,30 While reports
indicate that ELISAs based on the ORF2 region of
PCV-2 are useful, a direct comparison of the diagnostic
accuracy of currently available ELISAs has not yet
been performed to the authors’ knowledge. In addi-
tion, reports on the ability of the assays to detect and
differentiate between anti–PCV-2a, anti–PCV-2b, or
vaccine-induced antibodies are lacking.
To address the gaps in knowledge on current
PCV-2 ELISAs, the current study had the following
objectives: 1) to determine the diagnostic accuracy of
3 commonly used ELISAs, 2) to determine whether
each assay can detect and/or differentiate between
anti–PCV-2a and anti–PCV-2b antibodies, and 3) to




Animals were purchased from a PCV-2–negative herd,
weaned at 2 weeks of age, and transported to the Iowa
State University Livestock Infectious Disease Isolation
Facility (Ames, IA). On the day of delivery, the pigs were
randomly assigned to 1 of 7 rooms, each containing a 1.2 3
2.4 m raised wire deck pen equipped with 1 nipple drinker
and 1 self-feeder.
Experimental design
Three-week-old, conventional pigs were randomly allo-
cated to 7 groups and inoculated with either PCV-1, PCV-
2a, or PCV-2b; vaccinated with commercially available
PCV-2 vaccines; or left as negative controls as follows: 1)
negative controls (n 5 7), 2) PCV-2a (n 5 8), 3) PCV-2b (n
5 8), 4) PCV-1 (n5 8), 5) vaccine A (n5 8), 6) vaccine B (n
5 8), and 7) vaccine C (n 5 8). Upon arrival, pigs were
bled, and serum was tested by quantitative real-time PCV-2
polymerase chain reaction (PCR)23 to detect PCV-2 DNA
and by a PCV-2 fluorescent antibody test (FAT)24 to detect
anti–PCV-2 antibody. The experimental inoculations and
vaccinations were performed on trial day 0, at which time
the pigs were 3 weeks of age. All pigs were bled at weekly
intervals until trial day 49. All serum samples were tested
by 3 different ELISAs, and results were compared. The
experimental protocol was approved by the Iowa State
University Institutional Animal Care and Use Committee.
Inoculation
On trial day 0, pigs in the PCV-2a, PCV-2b, and PCV-1
groups were inoculated with 2 ml intramuscularly (IM) and
3 ml intranasally of 104.5 50% tissue culture infective dose
(TCID50)/ml of the appropriate virus inoculum. Animals
were inoculated with the following vaccines: PCV-2a group
(ISU-40895; GenBank accession number AF264042),
PCV-2b group (NC-16845; GenBank accession number
EU340258), and PCV-1 group (well-characterized PCV-1
clone).7 To confirm that the pigs in the PCV-1 group were
infected with PCV-1, serum samples were analyzed by PCR
for PCV-1 DNA.13 To confirm that PCV-2–inoculated pigs
were infected, serum samples from all pigs were tested by
PCR for PCV-2 DNA.23 In addition, a PCR product
recovered on trial day 49 from a PCV-2a– and a PCV-2b–
inoculated pig was sequenced and compared with the
respective inoculum.
Vaccination
Pigs in vaccine groups A, B, and C were vaccinated with
the respective vaccines according to the recommendations of
the manufacturers. Briefly, animals in the vaccine A groupa
received a 1-ml IM injection on trial day 0. Pigs in the
vaccine B groupb received a 2-ml IM injection on day 0 and a
second 2-ml IM injection on day 14. Pigs in the vaccine C
groupc received a 2-ml IM injection on trial day 0.
Serology
All serum samples collected from the pigs over time were
tested by a previously described indirect PCV-2 FAT24 and
by each of the following 3 ELISAs.
ELISA 1. This in-house, modified, indirect PCV-2
ELISA was performed as previously described.20 For this
assay, alternating rows on the ELISA plate were coated
with an ORF2 antigen (expressed in a BA expression
vector) or a BA antigen (BA expression vector without the
PCV-2a ORF2 insert). The PCV-2 isolate used for antigen
production, ISU-31 (GenBank accession number
AJ223185) had 99% similarity to the PCV-2a isolate used
for inoculation. The following modifications were made to
the previously described protocol: following incubation, the
plates were washed 5 times with 0.1 mol of phosphate
buffered salined (pH 7.2) and 0.1% Tween 20e using a
microplate washer. For visualization of results, 100 ml of
3,39,5,59-tetramethylbenzidinef was added to the wells.
Following a 15-min incubation at 25uC, the reaction was
stopped by adding 50 ml of 1 mol H2SO4. Results were
reported as sample-to-positive (S/P) ratios. All samples
were run in duplicate.
Initially, a corrected optical density (OD) value was
calculated for the 2 replicates of each sample and the
positive control: [(ORF2 OD + ORF2 OD)/2]2 [(BA OD +
BA OD)/2], where ORF2 is ORF2 antigen and OD is the
optical density value at 450 nm. To generate the S/P ratio,
the sample-corrected OD was divided by the positive
control–corrected OD20; S/P ratios ,0.2 were considered
negative, and S/P ratios $0.2 were considered positive. The
previously determined diagnostic sensitivity and specificity
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of this method using a 0.2 cutoff were 79.9% and 99.6%,
respectively.20
ELISA 2. This commercially available competitive
ELISAg was preformed according to the manufacturer’s
recommendations. The plates provided by the
manufacturer were coated with purified PCV-2 antigen.
Results were reported as an OD ratio of the sample OD
value to the negative control OD value. A plate-specific
cutoff was used such that samples with OD ratios #0.15
were considered positive, samples with an OD ratio of 0.15
to 0.20 were considered suspect, and samples with an OD
ratio $0.20 were considered negative as recommended by
the manufacturer.
ELISA 3. This commercially available capture PCV-2
ELISAh was also preformed according to the
manufacturer’s recommendations. The plates provided in
the assay came coated with monoclonal antibodies specific
for swine IgG. The antigen provided in the assay was a
recombinant PCV-2b protein produced through expression
in a BA vector (J. Delbecque, personal communication,
March 5, 2008). Results were reported as an OD ratio of
the sample OD value to the positive-control OD value. The
plate-specific cutoff was based on the OD 450 nm value of
the positive control 3 0.3 as recommended by the
manufacturer.
Statistics
Diagnostic accuracy of each assay was evaluated using
receiver operating characteristic (ROC) analysis. This
method results in area under the ROC curve (AUC) values
ranging from 0.5 to 1, where 0.5 indicates the test is not
discriminating between positive and negative animals and 1
indicates perfect discrimination.31 Area under the ROC
values were compared pairwise between tests using a
previously described method.11 All ROC calculations were
preformed on continuous data with infection status as the
indicator of true infection status using MedCalc.i Summary
statistics were calculated for all groups to assess the overall
quality of the data, including normality. Continuous data
were analyzed using multivariate analysis of variance. If a
significant (P , 0.05) change over time was noted for the
outcome variable, a nonparametric Kruskal-Wallis 1-way
analysis of variance (ANOVA) was performed at each time
point. If this nonparametric ANOVA test was significant
(P, 0.05), then pairwise Wilcoxon tests were used to assess
differences between groups. Statistical analysis was per-
formed using JMP software.j
Results
Diagnostic accuracy of assays
All assays had AUC values greater than or equal to
0.94 for all trial days using ROC-generated optimal
cutoffs; no statistical differences were noted among
the assays (Table 1). When data were dichotomized
using the manufacturer’s recommended cutoff values
(suspect samples were considered negative), the
sensitivity of all 3 assays was substantially reduced
at trial day 14 (Table 2). In contrast, the specificity of
ELISAs 2 and 3 was improved. When the manufac-
turer’s recommended cutoff was used at trial day 49,
the sensitivity of ELISAs 2 and 3 was substantially
reduced (Table 2). The number of pigs classified as
positive or negative based on S/P ratios of 0.2 (ELISA
1) or the manufacturer’s recommendations (ELISA 2
and 3) by the 3 ELISAs at trial days 14 and 49 is
presented in Table 3.
Detection of PCV-2a and PCV-2b
Infection status for PCV-2a and PCV-2b groups
was confirmed by PCR and sequence analysis
(Opriessnig T, Ramamoorthy S, Madson DM, et
al.: 2007, Experimental comparison of the virulence
of PCV2a and PCV2b isolates in a conventional pig
model. Proc Conf Res Workers Anim Dis 88:145). To
assess whether PCV-2a could be differentiated from
PCV-2b on any of the 3 ELISAs, the following null
hypothesis was tested: there is no difference between
PCV-2a and PCV-2b ELISA S/P or OD values on
ELISAs 1, 2, or 3. Statistical analysis using a Wilks’
lambda multivariate test indicated a significant (P ,
0.0001) difference over time between control and
PCV-2a and PCV-2b groups. A nonparametric
ANOVA at each time point revealed a significant
difference between negative controls and PCV-2a and
PCV-2b groups (P , 0.05) for all tests. Further
analysis using pairwise Wilcoxon tests indicated that
Table 1. Area under the receiver operating curve (AUC) values (6standard error) for each of the 3 enzyme-linked immunosorbent
assays (ELISAs) on different trial days.*
Assay
Trial day
14 21 28 35 42 49
ELISA 1 0.94 6 0.03 0.99 6 0.01 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00
ELISA 2 0.97 6 0.03 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00
ELISA 3 0.96 6 0.03 0.99 6 0.01 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00
IFAT 0.98 6 0.02 1.00 6 0.00 0.96 6 0.02 1.00 6 0.00 1.00 6 0.00 0.99 6 0.01
* Receiver operating characteristic analysis was preformed by denoting Porcine circovirus-2 subtype a (PCV-2a), PCV-2b, vaccine A,
vaccine B, and vaccine C pigs as true-positive (n 5 40) and negative controls and PCV-1 as true-negative animals (n 5 15). AUC values
range from 0.5 to 1, where 1 indicates the diagnostic test would perfectly discriminate between PCV-2–positive and –negative pigs when
using a given sample and 0.5 indicates there is no discrimination between groups. IFAT 5 indirect fluorescent antibody test.
746 Patterson et al.
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no significant differences were noted between PCV-2a
and PCV-2b groups on any of the assays (Fig. 1).
Detection of PCV-1
Serum samples from pigs in the PCV-1 group were
positive for PCV-1 DNA by PCR starting on trial day
7 (data not shown). No positive reactions were
detected in serum samples from PCV-1–inoculated
animals on any of the 3 ELISAs at any time during
the trial (data not shown).
Detection of antibodies in vaccinated animals
Mean and standard error S/P and OD ratios for each
group are provided in Figure 2. Results from ELISA 1
indicated that animals in the vaccine A group had
significantly lower mean S/P ratios in comparison with
PCV-2a– and PCV-2b–inoculated animals from trial
days 14 to 49 (P , 0.0005 for all days; Fig. 2a).
Animals in the vaccine B group also had significantly
lower mean S/P ratios from trial days 28 to 49 (P ,
0.03 for all days) in comparison to PCV-2–inoculated
animals. In contrast, animals in the vaccine C group
had a significantly (P5 0.01) higher mean S/P ratio at
trial day 28 in comparison to PCV-2–inoculated
animals (Fig. 2a). In contrast to ELISA 1, no
significant difference was noted between animals in
either the vaccine A or B group and the PCV-2–
inoculated animals based on ELISA 2 (P. 0.05 for all
days; Fig. 2b). Animals in the vaccine C group had a
significantly lower (more positive) OD ratio than that
in challenged animals at trial day 28 and 35 (P, 0.008
for both days; Fig. 2b). Results from ELISA 3 were
similar to ELISA 1 (Fig. 2c); animals in the vaccine A
group had significantly lower mean OD ratios in
comparison to PCV-2–inoculated animals at trial days
14 to 49 (P , 0.0006 for all days).
Following comparative analysis of the S/P values of
vaccinated and PCV-2–inoculated animals on ELISA
Table 2. Comparison of the sensitivity and specificity of each of the 3 enzyme-linked immunosorbent assays (ELISAs) at trial days
14 and 49 using various cutoffs for data dichotomization.
Assay
Trial day 14 Trial day 49
Cutoff Sensitivity (%) Specificity (%) Cutoff Sensitivity (%) Specificity (%)
ELISA 1 0.03* 87.5 100 0.34 100 100
0.20{ 45 100 0.20 100 100
ELISA 2 0.52* 97.5 93.3 0.25 100 100
0.15{ 22.5 100 0.15 57.5 100
ELISA 3 0.10* 85 93.3 0.15 100 100
0.451 30 100 0.45 75 100
* Cutoff determined by receiver operating characteristic analysis.
{ Cutoff determined from previous in-house data on test performance.
{ Cutoff determined by generating an optical density (OD) ratio by dividing the average sample OD value by the average OD value of
the negative control well; an OD ratio #0.15 was considered positive as recommended by the manufacturer.
1 Average plate cutoff. Individual plate cutoffs were determined by multiplying the average OD value of the positive control well by 0.3
as recommended by the manufacturer.
Table 3. Number of pigs classified as positive (+) or negative (2) by the 3 enzyme-linked immunosorbent assays (ELISAs) and a
Porcine circovirus-2 fluorescent antibody test (FAT) at trial days 14 and 49.*
Assay
Trial day 14 Trial day 49
ELISA 2 FAT ELISA 3 ELISA 2 FAT ELISA 3
+ 2 + 2 + 2 + 2 + 2 + 2
ELISA 1
+ 2 9 11 0 8 3 23 17 40 0 34 6
2 7 37 22 22 4 40 0 15 0 15 0 15
ELISA 3
+ 3 6 13 20 – – 22 12 34 6 – –
2 9 37 0 22 – – 1 20 0 15 – –
FAT
+ 8 25 – – – – 23 17 – – – –
2 1 21 – – – – 0 15 – – – –
* For ELISA 1, data were dichotomized such that sample-to-positive ratios $0.2 are considered positive. For ELISAs 2 and 3, data
were dichotomized as recommended by the manufacturer. Suspect samples were considered to be negative. For the FAT, data were
dichotomized such that titers $1:20 were considered positive.
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1, an S/P ratio decrease in the vaccine B group from
trial days 21 to 28 was noted. Further analysis at trial
day 21 revealed that in comparison to PCV-2a– and
PCV-2b–inoculated pigs, the OD values of the wells
containing BA antigen were significantly higher (P 5
0.0006) in the vaccine B group. This significant
increase in OD values of the BA wells for the vaccine
B group was apparent through the end of the trial
(P , 0.0001 for trial days 28 to 49). The effect of an
increase in OD values in the BA wells on the S/P ratio
Figure 1. Mean sample-to-positive ratio and standard error
for enzyme-linked immunosorbent assay (ELISA) 1 (A), and mean
optical density ratio and standard error for ELISA 2 (B) and
ELISA 3 (C). Controls (n 5 7; negative controls), Porcine
circovirus-2 subtype a (PCV-2a; n 5 8; inoculated with PCV-2
ISU 40895), and PCV-2b (n 5 8; inoculated with PCV-2
NC 16845).
Figure 2. Mean sample-to-positive ratio for enzyme-linked
immunosorbent assay (ELISA) 1 (A), and mean optical density
ratio and standard error for ELISA 2 (B) and ELISA 3 (C).
Negative controls (n 5 7), Porcine circovirus-2 (PCV-2; n 5 16;
combined PCV-2a and PCV-2b groups), vaccine A (n 5 8),
vaccine B (n 5 8), and vaccine C (n 5 8).
748 Patterson et al.
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is illustrated graphically in Figure 3. Optical density
values of the BA wells for all groups except the
vaccine B group were indistinguishable from back-
ground levels (data not shown). A similar increase in
OD values of the BA wells was not noted on any trial
days in the vaccine A or C group or with ELISAs 2
and 3.
Discussion
Receiver operating characteristic analysis has
become an increasingly valuable tool for comparison
of diagnostic tests.9,31 Unlike the kappa statistic,
ROC analysis determines the sensitivity and specific-
ity of the test based on the classification of true status
(infected vs. negative controls in the current study) at
multiple cutoffs by using the complete set of
continuous data.9 Interestingly, when the 3 ELISAs
were compared by ROC analysis, AUC values were
very high (.0.9). This indicated that all tests were
able to distinguish between negative and positive
animals using ROC analysis–generated optimal cut-
offs (cutoffs that provide the highest sensitivity and
specificity) based on continuous data from the
experiment. In contrast, when the manufacturer’s
cutoff values were used, sensitivity was substantially
reduced. While the current study was limited by a
small sample size, ROC analysis data suggest that
altering the cutoff value will increase the sensitivity of
ELISAs 2 and 3. Further studies with larger sample
sizes are necessary to determine an appropriate
cutoff. The manufacturers’ sensitivity and specificity
for ELISAs 2 and 3 at the recommended cutoffs were
not indicated on the package insert and could not be
compared with the results in the present study.
As most herds worldwide are seropositive for PCV-
2, ELISAs are most commonly used in cross-sectional
analyses to target optimal timing of vaccination.
Recent trends indicate an increased incidence of
detection of PCV-2b isolates and the association of
these strains with high mortality in herds with
increased incidence of severe mortality in swine
populations.5,12 This has stimulated interest in the
use of serological tests to monitor PCV-2b. As such,
there is a need to know whether commonly used
ELISAs are detecting both anti–PCV-2a and anti–
PCV-2b antibodies. Results of the current study
indicate that all 3 ELISAs can detect both antibodies
but cannot differentiate between anti–PCV-2a and
anti–PCV-2b antibodies. This was independent of the
origin of the coating antigen used since at least
1 assay used PCV-2a (ELISA 1) and 1 assay used
PCV-2b (ELISA 3) for antigen production.
Nucleotide sequence homology between PCV-1 and
PCV-2 ranges from 69% to 79.5%.10,18,19 A previous
report indicated that there was no serological cross-
reactivity between the ORF2 region of PCV-2 and
PCV-117 or between PCV-1 and PCV-2 polyclonal
antisera and monoclonal antibodies using an indirect
FAT.12 Conversely, ORF1 regions of PCV-2 do
exhibit serological cross-reactivity with PCV-1.17
Results of the current study confirm previous reports
and indicate that PCV-1–inoculated animals were not
detected with any of the ELISAs evaluated. Although
the PCV-1–inoculated animals were found to be
PCV-1 positive by PCR, an anti–PCV-1 ELISA assay
was not available to confirm the presence of anti–
PCV-1 antibodies in these animals.
Following the introduction of vaccines into the U.S.
market in 2006, the prevalence of seropositive animals
has grown steadily. Therefore, an assay able to
differentiate vaccinated and naturally infected animals
would be a useful tool for veterinary practitioners in
situations in which they are assessing vaccination
protocol compliance issues. Although distinguishing
vaccinated animals based on either an S/P or OD ratio
would not be possible based on the results of the
current study, using the OD value of the BA well on
ELISA 1 may provide a means of differentiation for
vaccine B. In contrast to the other 2 ELISAs, ELISA 1
uses BA derived from a baculovirus expression vector
that does not contain the PCV-2 ORF2 insert to
control for nonspecific background binding.20 Serum
samples from both vaccine A and B group pigs were
expected to have increased OD values for the BA wells
as both products use the baculovirus expression vector
for antigen production. Interestingly, only the serum
samples from the vaccine B group showed a significant
increase in OD value in the BA well. Because the
increase in the OD value of the BA well occurred
Figure 3. Mean and standard error sample-to-positive (S/P)
ratio and average optical density for the baculovirus (BA) antigen
and open reading frame 2 (ORF2) wells on enzyme-linked
immunosorbent assay (ELISA) 1. All values are for animals in
the vaccine B (n 5 8) group.
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following the administration of the second dose of
vaccine B, it can be speculated that 2 doses of vaccine
A may lead to the same response as seen with vaccine
B. Alternatively, differences in vaccine preparation or
type of adjuvant between the 2 products may account
for the lack of cross-reactivity in BA well OD values of
animals in the vaccine A group.
While providing a means of differentiating vacci-
nated and naturally infected animals, significant
increases in OD values alone should be interpreted
carefully as results could be confounded by vaccina-
tion with other products in which the BA vector is
used, serum factors other than antibodies against BA,
or other unknown nonspecific reactions. These
nonspecific reactions could falsely elevate the OD
value. As an S/P ratio is not generated when looking
at the individual OD value from the BA well, no
control for this is in place with the current assay.
The lack of increase of the S/P ratio in ELISA 1 for
the vaccine B group cannot be interpreted as a lack of
seroconversion because a high OD value for the BA
could be lowering the S/P ratio. Therefore, the OD
value for the BA well should be observed in addition
to the S/P ratio, or 1 of the other 2 assays should be
used to assess seroconversion with this product.
Reasons for the decreased average OD on ELISA 3
for the vaccine A group may include vaccine
preparation, type of adjuvant, or dose of administra-
tion. It should be noted that while antibody levels
following vaccination were determined in the current
study, there was no challenge of animals. Therefore,
the ability of vaccination to protect against disease
was not evaluated in this trial.
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